|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.99 USD | -2.66% |
|
+7.07% | 0.00% |
| 05-14 | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
| 05-09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
CG Oncology, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 16.93 million compared to USD 8.67 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 3.22 a year ago.
Diluted loss per share from continuing operations was USD 0.36 compared to USD 3.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 2.05B | |
| +64.92% | 62.59B | |
| -1.85% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.05% | 26.21B | |
| -21.96% | 19.09B | |
| +4.21% | 13.08B | |
| +25.74% | 12.26B | |
| +27.42% | 12.05B |
CG ONCOLOGY, INC. 
